267 filings
Page 10 of 14
8-K
ievpr
16 Oct 17
Heat Biologics Announces Pricing for Rights Offering to Stockholders
12:00am
8-K
ow4l6tn
28 Sep 17
Heat Biologics Announces Expected Calendar for Rights Offering
12:00am
8-K
digkxrcj5 xva
27 Sep 17
Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma
12:00am
8-K
m7mfe3mqvzu4vdt lbu9
15 Sep 17
Heat Biologics Announces Common Stock Rights Offering in Form S-1 Filing
12:00am
8-K
00owe4y7t7 tg4a
14 Sep 17
Heat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance
12:00am
8-K
pdg6uiiwu7a33uzie
12 Sep 17
Other Events
12:00am
8-K
osd4hjofjk4zck
14 Aug 17
Heat Biologics Reports Second-quarter 2017 Results
12:00am
8-K/A
80d6nsc 7pmb6ci
17 Jul 17
Material Modifications to Rights of Security Holders
12:00am
8-K/A
hnqslqhpj 4aded
11 Jul 17
Financial Statements and Exhibits
12:00am
8-K
cf0x6pq1bzoffe215mx
30 Jun 17
Entry into a Material Definitive Agreement
12:00am
8-K
562hfv9zgq uhgj3w7gx
31 May 17
Other Events
12:00am
8-K
qbfpvedyjgx29q mv
11 May 17
Heat Biologics Provides Business and Clinical Update
12:00am
8-K
g7i8sqi
3 May 17
Heat Biologics Announces Completion of Acquisition of Pelican Therapeutics
12:00am
8-K
3qttm31a8 7k
7 Apr 17
Entry into a Material Definitive Agreement
12:00am
8-K
ruvxr h5r
31 Mar 17
Heat Biologics Reports Fiscal Year 2016 Financial Results
12:00am
8-K
z0x8jfgf
24 Mar 17
Heat Biologics Announces Proposed Public Offering of Common Stock
12:00am
8-K
dh2qpvyew3hln
23 Mar 17
Results of Operations and Financial Condition
12:00am
8-K
xnia3gcm296pr41
21 Mar 17
Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
12:00am
8-K
dfhdc5dq0t9 owv
16 Mar 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
igqxl70x5uk0sd iwin
13 Mar 17
Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
12:00am